New Data Published in Journal of Opioid Management Show Ameritox’s(R) Proprietary Medication Monitoring Algorithm Superior to Traditional Urine Testing in Discriminating Oxycontin(R) Drug Regimens

A study published in the November/December issue of the Journal of Opioid Management revealed that a proprietary algorithm offered by Ameritox®, applied to urine drug levels of OxyContin® C-II (oxycodone HCl controlled-release) Tablets, demonstrated excellent ability to differentiate among three different doses of OxyContin® (oxycodone hydrochloride) compared to a traditional urine drug level test. The proprietary algorithm is applied within the company’s Rx Guardian(SM) pain medication monitoring process, designed to provide physicians with additional information about patients’ pain medication use.

Read more ›